GB0922589D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB0922589D0
GB0922589D0 GBGB0922589.7A GB0922589A GB0922589D0 GB 0922589 D0 GB0922589 D0 GB 0922589D0 GB 0922589 A GB0922589 A GB 0922589A GB 0922589 D0 GB0922589 D0 GB 0922589D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0922589.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Priority to GBGB0922589.7A priority Critical patent/GB0922589D0/en
Publication of GB0922589D0 publication Critical patent/GB0922589D0/en
Priority to CN201080059321.9A priority patent/CN102791708B/zh
Priority to MX2012007274A priority patent/MX2012007274A/es
Priority to RU2012131115/04A priority patent/RU2579513C2/ru
Priority to DK10800980.4T priority patent/DK2516435T3/da
Priority to HK12111698.8A priority patent/HK1171013B/en
Priority to SG2012041232A priority patent/SG181517A1/en
Priority to PCT/GB2010/002329 priority patent/WO2011077098A1/en
Priority to EP10800980.4A priority patent/EP2516435B8/en
Priority to KR1020127019033A priority patent/KR20140015157A/ko
Priority to NZ600453A priority patent/NZ600453A/xx
Priority to JP2012545434A priority patent/JP5923043B2/ja
Priority to ES10800980.4T priority patent/ES2503794T3/es
Priority to BRBR112012015677-2A priority patent/BR112012015677A2/pt
Priority to US13/517,219 priority patent/US9221838B2/en
Priority to CA2783340A priority patent/CA2783340C/en
Priority to PL10800980T priority patent/PL2516435T3/pl
Priority to AU2010334591A priority patent/AU2010334591C1/en
Priority to PT108009804T priority patent/PT2516435E/pt
Priority to SI201030774T priority patent/SI2516435T1/sl
Priority to IL220153A priority patent/IL220153A/en
Priority to CY20141100899T priority patent/CY1115686T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
GBGB0922589.7A 2009-12-23 2009-12-23 Pharmaceutical compounds Ceased GB0922589D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB0922589.7A GB0922589D0 (en) 2009-12-23 2009-12-23 Pharmaceutical compounds
SI201030774T SI2516435T1 (sl) 2009-12-23 2010-12-23 Inhibitorji AKT-aktivnosti
NZ600453A NZ600453A (en) 2009-12-23 2010-12-23 Inhibitors of akt activity
ES10800980.4T ES2503794T3 (es) 2009-12-23 2010-12-23 Inhibidores de la actividad Akt
RU2012131115/04A RU2579513C2 (ru) 2009-12-23 2010-12-23 Ингибиторы активности акт
DK10800980.4T DK2516435T3 (da) 2009-12-23 2010-12-23 Inhibitorer af AKT-aktivitet
HK12111698.8A HK1171013B (en) 2009-12-23 2010-12-23 Inhibitors of akt activity
SG2012041232A SG181517A1 (en) 2009-12-23 2010-12-23 Inhibitors of akt activity
PCT/GB2010/002329 WO2011077098A1 (en) 2009-12-23 2010-12-23 Inhibitors of akt activity
EP10800980.4A EP2516435B8 (en) 2009-12-23 2010-12-23 Inhibitors of akt activity
KR1020127019033A KR20140015157A (ko) 2009-12-23 2010-12-23 Ａｋｔ 활성 억제제
CN201080059321.9A CN102791708B (zh) 2009-12-23 2010-12-23 Akt活性的抑制剂
JP2012545434A JP5923043B2 (ja) 2009-12-23 2010-12-23 Ａｋｔ活性の阻害剤
MX2012007274A MX2012007274A (es) 2009-12-23 2010-12-23 Inhibidores de la actividad de akt.
BRBR112012015677-2A BR112012015677A2 (pt) 2009-12-23 2010-12-23 Compostos farmacêuticos.
US13/517,219 US9221838B2 (en) 2009-12-23 2010-12-23 Inhibitors of AKT activity
CA2783340A CA2783340C (en) 2009-12-23 2010-12-23 Inhibitors of akt activity
PL10800980T PL2516435T3 (pl) 2009-12-23 2010-12-23 Inhibitory aktywności AKT
AU2010334591A AU2010334591C1 (en) 2009-12-23 2010-12-23 Inhibitors of AKT activity
PT108009804T PT2516435E (pt) 2009-12-23 2010-12-23 Inibidores da actividade de akt
IL220153A IL220153A (en) 2009-12-23 2012-06-04 Activity inhibitors of akt
CY20141100899T CY1115686T1 (el) 2009-12-23 2014-10-31 Αναστολεις της δρασης της ακτ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0922589.7A GB0922589D0 (en) 2009-12-23 2009-12-23 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB0922589D0 true GB0922589D0 (en) 2010-02-10

Family

ID=41716932

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0922589.7A Ceased GB0922589D0 (en) 2009-12-23 2009-12-23 Pharmaceutical compounds

Country Status (21)

Country Link
US (1) US9221838B2 (https=)
EP (1) EP2516435B8 (https=)
JP (1) JP5923043B2 (https=)
KR (1) KR20140015157A (https=)
CN (1) CN102791708B (https=)
AU (1) AU2010334591C1 (https=)
BR (1) BR112012015677A2 (https=)
CA (1) CA2783340C (https=)
CY (1) CY1115686T1 (https=)
DK (1) DK2516435T3 (https=)
ES (1) ES2503794T3 (https=)
GB (1) GB0922589D0 (https=)
IL (1) IL220153A (https=)
MX (1) MX2012007274A (https=)
NZ (1) NZ600453A (https=)
PL (1) PL2516435T3 (https=)
PT (1) PT2516435E (https=)
RU (1) RU2579513C2 (https=)
SG (1) SG181517A1 (https=)
SI (1) SI2516435T1 (https=)
WO (1) WO2011077098A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
CA2971763A1 (en) * 2014-12-23 2016-06-30 Bergenbio Asa Inhibitors of akt kinase
CN111943962A (zh) * 2015-02-27 2020-11-17 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
US11208478B2 (en) 2016-08-07 2021-12-28 The Wistar Institute Of Anatomy And Biology Methods of detecting and treating a tumor expressing pT346 PDK1
PE20200696A1 (es) * 2017-06-22 2020-06-16 Curadev Pharma Ltd Moduladores de moleculas pequenas de sting humana
KR102917509B1 (ko) 2017-09-07 2026-01-26 오거스타 유니버시티 리서치 인스티튜트, 인크. 특이적 akt3 활성제 및 이의 용도
GB2600384A (en) * 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2025250545A1 (en) * 2024-05-28 2025-12-04 Alterome Therapeutics, Inc. Akt1 modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76853A (en) * 1994-11-14 1997-12-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
TWI301760B (en) * 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7910561B2 (en) * 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8008317B2 (en) * 2005-06-10 2011-08-30 Merck Sharp & Dohme Corp. Inhibitors of akt activtiy
CA2656507C (en) * 2006-07-17 2012-03-20 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
JP2010512312A (ja) 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7999107B2 (en) * 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
CA2726317A1 (en) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2299825B1 (en) 2008-06-03 2013-07-31 Merck Sharp & Dohme Corp. Inhibitors of akt activity

Also Published As

Publication number Publication date
CN102791708B (zh) 2016-03-02
HK1171013A1 (en) 2013-03-15
US9221838B2 (en) 2015-12-29
CY1115686T1 (el) 2017-01-25
WO2011077098A9 (en) 2012-04-19
IL220153A0 (en) 2012-07-31
PT2516435E (pt) 2014-11-13
CA2783340C (en) 2015-11-24
RU2012131115A (ru) 2014-01-27
MX2012007274A (es) 2012-10-03
EP2516435B1 (en) 2014-08-06
BR112012015677A2 (pt) 2015-06-30
CN102791708A (zh) 2012-11-21
JP2013515710A (ja) 2013-05-09
AU2010334591B2 (en) 2014-04-10
SG181517A1 (en) 2012-07-30
AU2010334591A1 (en) 2012-06-21
JP5923043B2 (ja) 2016-05-24
CA2783340A1 (en) 2011-06-30
US20130116243A1 (en) 2013-05-09
IL220153A (en) 2015-05-31
WO2011077098A1 (en) 2011-06-30
PL2516435T3 (pl) 2015-01-30
NZ600453A (en) 2013-10-25
EP2516435B8 (en) 2014-10-15
AU2010334591C1 (en) 2014-07-31
ES2503794T3 (es) 2014-10-07
KR20140015157A (ko) 2014-02-06
SI2516435T1 (sl) 2014-12-31
RU2579513C2 (ru) 2016-04-10
DK2516435T3 (da) 2014-10-13
EP2516435A1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
ZA201104336B (en) Pharmaceutical compounds
GB0816372D0 (en) Pharmaceutical compounds
IL215451A0 (en) Pharmaceutical composition
GB0820819D0 (en) Pharmaceutical compounds
GB0801416D0 (en) Pharmaceutical compounds
GB201008005D0 (en) Pharmaceutical compounds
EP2379077A4 (en) PHARMACEUTICAL COMPOSITION
GB0816371D0 (en) Pharmaceutical compounds
GB0812969D0 (en) Pharmaceutical compounds
SI2271618T1 (sl) Farmacevtske spojine
GB0816370D0 (en) Pharmaceutical compounds
GB0922589D0 (en) Pharmaceutical compounds
GB201020161D0 (en) Pharmaceutical compounds
GB0810857D0 (en) Pharmaceutical compounds
GB0908905D0 (en) Pharmaceutical compounds
GB0917775D0 (en) Novel pharmaceutical compounds
GB0919650D0 (en) Pharmaceutical composition
GB0917774D0 (en) Novel pharmaceutical compounds
GB0913850D0 (en) Pharmaceutical compounds
GB0911699D0 (en) Pharmaceutical compounds
GB0915678D0 (en) Pharmaceutical compounds
GB0922523D0 (en) Pharmaceutical compounds
GB0917677D0 (en) Pharmaceutical compounds
GB0916458D0 (en) Pharmaceutical compounds
GB0910772D0 (en) Pharmaceutical

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)